Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Venous Thrombosis 1Thrombocytopenia 1Pulmonary Embolism 1Liver Neoplasms 1Hemorrhage 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5pembrolizumab 4Cyclophosphamide 4olaparib 3liposomal doxorubicin 3fludarabine 3ribociclib 2palbociclib 2mirvetuximab soravtansine 2Topotecan 2Nivolumab 2Letrozole 2Fulvestrant 2Blood Specimen Collection 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1niraparib 1lenvatinib 1isoquercitrin 1fludarabine phosphate 1durvalumab 1cemiplimab 1abemaciclib 1Tinzaparin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1SLC25A33 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Ovarian Epithelial × Tinzaparin × Clear all
NCT05284552 2026-05-11

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

University Hospital, Linkoeping

Phase 2 Recruiting
40 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡